PeptiSystems Strengthens Leadership in Quality Assurance and Engineering with new VP appointment

19th of February, 2025 - Uppsala, Sweden,

​

PeptiSystems, a biotech company specializing in innovative manufacturing solutions for peptide and oligonucleotide drugs, is pleased to announce the appointment of Mårten Bergström as Vice President of Quality Assurance and Engineering. With this appointment, PeptiSystems strengthens its leadership in quality and regulatory compliance, supporting the company’s continued growth in a rapidly evolving industry.

​

PeptiSystems’ proprietary flowthrough, column-based technology optimizes synthesis efficiency, reduces material waste, and ensures compliance with the highest industry standards. By enabling pharmaceutical companies and CDMOs to scale production of peptide and oligonucleotide therapeutics, the technology supports advancements in next-generation manufacturing. As PeptiSystems continues to innovate and scale its operations, reinforcing leadership in quality assurance remains a priority.

​

Mårten Bergström joins PeptiSystem with over 30 years of experience in product development and quality assurance within the diagnostics and life science industries. His career includes leadership roles at Gyros Protein Technologies and Pharmacia Diagnostics (now ThermoFisher Scientific), focusing on quality management, regulatory compliance, and the commercialization of instruments and software. Most recently, he served as Global Director of Quality Assurance at Gyros Protein Technologies, responsible for quality strategies and process optimization.

​

As VP of Quality Assurance and Engineering, Mårten will have a central role in ensuring that PeptiSystems’ synthesizers meet strict industry requirements for peptide and oligonucleotide manufacturing.

​

"We are thrilled to welcome Mårten Bergström to our PeptiSystems leadership team. Mårten brings a wealth of experience and a deep commitment to excellence, which will be invaluable as we continue refining our engineering and quality standards. His expertise and leadership will play a key role in driving innovation and enabling us to consistently deliver the highest quality to our customers," says Karin Granath, CEO of PeptiSystems.

​

"I am excited to join PeptiSystems and contribute to the company’s mission of advancing high-quality, innovative solutions for peptide and oligonucleotide manufacturing. I look forward to working with the team to drive excellence in quality assurance and engineering. PeptiSystems is at the forefront of delivering cutting-edge technology, and I am eager to be part of this journey,” comments Mårten Bergström.

​

For more information, please contact:
Karin Granath, CEO
Phone: +46 702-82 07 47
Email: karin.granath@peptisystems.com  

 

About PeptiSystems AB
PeptiSystems is a biotech company developing a new generation of flow-through instruments for peptide and oligonucleotide therapeutics synthesis. Utilizing proprietary flow-through column technology, PeptiSystems' instruments significantly reduce production times, enhance synthesis control, and minimize raw material consumption while maintaining high purity and yield. With scalability in mind, these next-generation synthesis instruments seamlessly adapt from small-scale development to large-scale production, enabling pharmaceutical companies and CDMOs to meet the growing global demand for high-performance, cost-effective, and sustainable manufacturing processes. PeptiSystems is headquartered in Uppsala, Sweden. For more information, please visit www.peptisystems.com and follow us on LinkedIn.